熱門資訊> 正文
在第三阶段nex-z试验中发生严重不良事件后，intlia股价暴跌
2025-10-27 20:32
- Intellia Therapeutics (NASDAQ:NTLA) shares are down ~45% in premarket trading Monday after pausing dosing in two phase 3 trials for nexiguran ziclumeran (nex-z).
- The pause is due to a report of a patient who was hospitalized with Grade 4 liver transaminases and increased total bilirubin in the MAGNITUDE trial, which is evaluating the candidate in transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The other trial, MAGNITUDE-2, is in transthyretin amyloidosis with polyneuropathy (ATTR-PN).
- Enrollment for both trials is also on hold.
- Currently, 650 patients are enrolled in MAGNITUDE, and 47 patients in MAGNITUDE-2. More than 450 are estimated to have been dosed.
More on Intellia Therapeutics
- Crispr And Intellia: Advancing In Vivo Gene Editing As 2025 Results Strengthen Investment Outlook
- Intellia Therapeutics: Full Trial Enrollment Wows Market - Underlines Buy Thesis
- Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade)
- Intellia Therapeutics upgraded by Citizens JMP on HAE opportunity, shares rise 6%
- Cathie Wood's Ark Invest weekly recap: lifts stake in Bullish and Brera, trims Roku and Tempus AI
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
